Previous close | 4.10 |
Open | 6.90 |
Bid | 6.80 |
Ask | 8.30 |
Strike | 5.00 |
Expiry date | 2024-05-17 |
Day's range | 6.90 - 6.90 |
Contract range | N/A |
Volume | |
Open interest | 27 |
Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the "Inducement Plan").